Warfarin is an oral anticoagulant used to prevent and treat thromboembolism. The narrow therapeutic index of this medication coupled with the considerable intra- and inter-patient variability in response markedly complicate management. Clinically significant adverse events can result from under- or over-anticoagulation, namely thromboembolism or significant bleeding respectively.
A crucial requirement for optimisation of safety and effectiveness of therapeutic range therapy is therefore regular measurement of the international normalised ratio (INR) to evaluate the impact of warfarin, followed by appropriate dose adjustments to maintain the INR within the target.
What are the key issues that patients need to know?
The Warfarin Education Programme consists of a toolkit of resources suitable for carry out structured, comprehensive, one-on-one education for all patients on warfarin.
For further information, please email firstname.lastname@example.org.
To order flipchart or patient information cards, please complete form [PDF, 10 KB].